Skip to main content
SoftOx Solutions AS logo

SoftOx Solutions AS — Investor Relations & Filings

Ticker · SOFTX ISIN · NO0010811961 LEI · 549300AETMWJS91G4A50 OL Manufacturing
Open in API
Filings indexed 572 across all filing types
Latest filing 2022-05-19 Regulatory Filings
Country NO Norway
Listing OL SOFTX

About SoftOx Solutions AS

https://soft-ox.com/

SoftOx Solutions AS is a clinical-stage pharmaceutical company that has developed a patented, non-toxic antimicrobial technology. The technology is based on a stabilized formulation of hypochlorous acid (HOCl), an endogenous molecule used by the human immune system to combat pathogens. It is designed to be highly effective against a broad spectrum of bacteria, viruses, and fungi, and to eradicate and prevent biofilm infections. A key feature of the technology is that its mode of action does not induce antimicrobial resistance (AMR). The company's development pipeline focuses on significant health challenges, with a lead candidate, SoftOx Inhalation Solution (SIS), for treating airway infections, as well as other applications in wound care and disinfection.

Recent filings

Filing Released Lang Actions
SOFTOX SOLUTIONS AS: ANNOUNCES POSITIVE PHASE 1 RESULTS FOR SOFTOX INHALATION SOLUTION (SIS)
Regulatory Filings Classification · 95% confidence The document is a press release titled "SOFTOX SOLUTIONS AS: ANNOUNCES POSITIVE PHASE 1 RESULTS FOR SOFTOX INHALATION SOLUTION (SIS)". It details the top-line results of a clinical trial (Phase 1 study) regarding safety and tolerability, which is a key component of early-stage drug development reporting. This type of announcement, focusing on clinical trial outcomes and future development plans (Phase 2), is typically classified as an Earnings Release (ER) if it's a periodic update, or more specifically, a general announcement related to company progress. Since it is an announcement of clinical trial results, it is not a full Annual Report (10-K), Interim Report (IR), or a formal Audit Report (AR). Given the context of announcing key operational/development milestones, it fits best under the general category of an Earnings Release (ER) which often includes operational highlights, or potentially a Regulatory Filing (RNS) if it were less specific. However, the content is a direct announcement of positive results, which is a common feature of an ER or a general operational update. Since there is no specific category for 'Clinical Trial Results Announcement', and it is not a formal financial report, ER is the closest fit for a major operational/results announcement, although it is not strictly quarterly earnings. Given the options, and that it is a major announcement of positive results, ER is the most appropriate classification for a significant operational update outside of formal financial statements. The document length (3547 chars) is substantial enough to be more than just a brief RPA.
2022-05-19 English
SoftOx Solutions AS: to attend and host an educational symposium at the European Wound Management Association Conference
Regulatory Filings Classification · 100% confidence The document is a short announcement from SoftOx Solutions AS stating that the company will attend and host a symposium at the European Wound Management Association (EWMA) Conference. It details the title, date, time, speakers, and agenda for the symposium. Crucially, it mentions that a recording of the symposium will be made available on the company's website under 'investor-presentations/'. Since this document is an announcement about an event and the subsequent availability of presentation material, and it is relatively short (3737 characters), it fits the description of a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Given that it is announcing the availability of presentation content (even if the presentation itself is not attached here), RPA is a strong candidate, but since it is primarily a news announcement about participation and hosting an event, RNS (General regulatory announcement/news release) is the most appropriate general category for corporate news that doesn't fit specific financial report types like 10-K, ER, or IR. It is not a full presentation (IP) or a transcript (CT). I will classify it as RNS as it is a general corporate news release.
2022-05-18 English
SoftOx Solutions AS: Annual general meeting held
AGM Information Classification · 100% confidence The document is explicitly titled "MINUTES FROM ANNUAL GENERAL MEETING" and details the resolutions passed during a meeting held on May 12, 2022. Key items discussed include the approval of the annual accounts/report, remuneration guidelines, election of board members, and authorization for share capital increases. This content directly corresponds to the documentation generated following an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R (AGM Information).
2022-05-12 English
SoftOx Solutions AS: Annual general meeting held
AGM Information Classification · 100% confidence The document is explicitly titled "PROTOKOLL FRA ORDINÆR GENERALFORSAMLING" (Minutes from the Annual General Meeting) for SoftOx Solutions AS, dated May 12, 2022. It details the proceedings, resolutions passed regarding the annual report, director remuneration, option schemes, board elections, and amendments to the company's articles of association. This content directly corresponds to the documentation generated following an Annual General Meeting. Therefore, the appropriate classification is AGM-R (AGM Information).
2022-05-12 Norwegian
SoftOx Solutions AS: Annual general meeting held
AGM Information Classification · 99% confidence The document explicitly mentions 'Annual general meeting held' in the title and body. It confirms that all proposals were resolved as presented in the notice for the annual general meeting and refers to the 'minutes from the general meeting attached hereto'. This content directly relates to the proceedings and outcomes of the Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R). The document length is short (1121 chars), but since it summarizes the outcome of the AGM rather than just announcing the publication of minutes, AGM-R is more specific than RPA or RNS.
2022-05-12 English
SoftOx Solutions AS: The SBE-01 phase 1 clinical study enters the final phase 1b
Legal Proceedings Report Classification · 99% confidence The document is a short announcement from a clinical-stage biopharmaceutical company (SoftOx Solutions AS) detailing the progress of a specific clinical study (SBE-01 phase 1). It reports that one phase (1a) has concluded and the study is moving to the next phase (1b) based on the Safety Monitoring Committee's recommendation. This type of update, focusing on clinical trial milestones and safety/efficacy measures, is typically classified as an Investor Presentation (IP) if it were a detailed deck, or more commonly, a general regulatory/investor update. Since it is a brief announcement about operational progress rather than a formal financial report (10-K, IR, ER) or a specific transaction (DIV, CAP, DIRS), and it doesn't fit the definitions for AGM-R, MANG, CT, DVA, DLST, SR, FS, CGR, IRAT, LTR, TAR, MRQ, NAV, DEF 14A, RPA, SHA, or POS, it falls best under the general category for investor-relevant news that isn't a formal financial filing or a presentation. Given the options, and since it's a specific operational update that is not a formal financial report, it is most closely aligned with general investor news. However, if this were a standard press release detailing operational milestones, it often gets categorized as an Investor Presentation (IP) if it contains strategic context, or sometimes as Regulatory Filings (RNS) if it's a mandatory disclosure. Since it details clinical progress which is key investor information, and it's not a formal financial report, 'IP' (Investor Presentation) is a plausible fit if we interpret 'presentation' broadly as an update package, but 'RNS' (Regulatory Filings/General Announcement) is the safest fallback for non-standard operational news. Given the context of biotech updates, these milestone announcements are often treated as general regulatory disclosures. I will classify it as RNS as it is a general operational announcement that doesn't fit the more specific categories.
2022-05-11 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.